PubMed دسترسی آزاد

Pharmacovigilance in the treatment of cutaneous leishmaniasis: adverse event profile at a reference center.

Ana Luiza Silva Rezende, Janaína de Pina Carvalho, Beatriz Prado Noronha, Sarah Nascimento Silva• 2026• Revista da Sociedade Brasileira de Medicina Tropical
استودیوی صوتی مقاله

پخش حرفه‌ای فارسی و انگلیسی

در حال بررسی نسخه‌های صوتی ذخیره‌شده…

صوت تولیدشده با هوش مصنوعی است. برای کاربرد علمی یا درمانی، متن و منبع اصلی را بررسی کنید.
خواندن هوشمند فارسی و انگلیسی در حال آماده‌سازی صداهای مرورگر…
تنظیم صدای طبیعی و سرعت

صداهایی که در نامشان «Natural»، «Neural» یا «Online» دیده می‌شود معمولاً طبیعی‌ترند. انتخاب صدا به صداهای نصب‌شده در ویندوز و مرورگر شما بستگی دارد.

چکیده اصلی

BACKGROUND: Cutaneous leishmaniasis treatment is frequently associated with adverse events (AEs). We investigated the profile of AEs and examined their associations. METHODS: This prospective observational study was conducted at a Brazilian reference center to describe AEs according to their occurrence rate, severity, and seriousness. RESULTS: Among 318 AEs recorded in 92 patients, the highest AE occurrence rate was among those treated with miltefosine. The highest rate of serious AEs was among patients treated with liposomal amphotericin B. Local therapy using meglumine antimoniate showed a more favorable safety profile. CONCLUSION: The different profiles highlight the importance of pharmacovigilance in real-world settings.

متن کامل اصلی

نسخه دارای مجوز در منبع علمی در دسترس است.

لینک مستقیم از metadata منبع گرفته شده و در تب جدید باز می‌شود.

باز کردن متن کامل
در همین زیرشاخه

مقاله‌های مرتبط

PubMed2026

GLP-1R expression and dermatological diseases: a mendelian randomization and real-world study.

BACKGROUND: Although glucagon-like peptide-1 receptor (GLP-1R) is widely expressed in multiple tissues and organs including skin and subcutaneous tissue, with diverse physiological roles in metabolism and immunity, the potential causal association between GLP-1R expression and dermatological diseases remains unclear. METHODS: Available cis-expression quantitative trait loci (cis-eQTLs) were selected as genetic instruments for GLP-1R ex…

PubMed2026

Machine learning-driven pharmacovigilance of antidiabetic drugs: comparative reporting patterns and classification of serious adverse events.

PURPOSE: This study aims to evaluate the comparative adverse drug event (ADE) reporting patterns associated with antidiabetic drugs and develop machine learning (ML)-based classification models for the seriousness of reported ADEs. METHODS: We performed a retrospective analysis of 28,633 antidiabetic-related ADEs reported to the Korea Institute of Drug Safety and Management- Korea Adverse Event Reporting System database (KAERS DB 2505A…

PubMed2026

Artificial Intelligence Across the Pharmaceutical Life Cycle: Implications for Industry-Based Clinical Pharmacists.

Artificial intelligence (AI) is increasingly shaping the pharmaceutical industry. This ACCP commentary examines the implications of AI for industry-based clinical pharmacists across the pharmaceutical life cycle, including drug development, regulatory affairs, medical affairs, health economics and outcomes research, and pharmacovigilance. Artificial intelligence-enabled tools may support target identification, clinical trial design, re…

PubMed2026

FAERS-based pharmacovigilance study of sevoflurane-associated adverse events: A 20-year comprehensive analysis.

BACKGROUND: Sevoflurane, an ether-derived inhalational anesthetic widely used for general anesthesia, requires comprehensive safety evaluation. OBJECTIVES: This study aimed to identify sevoflurane-associated adverse events and detect unexpected safety signals using data from the FDA Adverse Event Reporting System (FAERS). METHODS: We analyzed FAERS data from the first quarter of 2004 through the first quarter of 2024, applying four dis…